Clinical Trials Browser

Phase 1 × Terminated × selinexor × Clear all

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT05093608 2022-10-17

SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma

Phase 1 Terminated

2 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02384850 2022-04-08

SENTINEL

Phase 1 Terminated

10 enrolled 13 charts

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT02283359 2016-01-15

Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus

Phase 1 Terminated

3 enrolled

Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Neoplasm Metastasis, Recurrence, Stomach Neoplasms